Literature DB >> 24243994

Issues on results of the external quality assessment for proviral DNA testing of HIV-1 tropism in the Maraviroc Switch collaborative study.

Jörg Berg1, Christian Paar, Heribert Stoiber, Thomas Klimkait.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24243994      PMCID： PMC3838091          DOI： 10.1128/JCM.02124-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  6 in total

1.  Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.

Authors:  Valentina Svicher; Claudia Alteri; Marco Montano; Roberta D'Arrigo; Massimo Andreoni; Gioacchino Angarano; Andrea Antinori; Guido Antonelli; Tiziano Allice; Patrizia Bagnarelli; Fausto Baldanti; Ada Bertoli; Marco Borderi; Enzo Boeri; Isabella Bon; Bianca Bruzzone; Anna Paola Callegaro; Maria Rosaria Capobianchi; Giampiero Carosi; Roberto Cauda; Francesca Ceccherini-Silberstein; Massimo Clementi; Antonio Chirianni; Manuela Colafigli; Antonella D'Arminio Monforte; Andrea De Luca; Antonio Di Biagio; Giuseppe Di Nicuolo; Giovanni Di Perri; Massimo Di Pietro; Fabiola Di Santo; Lavinia Fabeni; Giovanni Fadda; Massimo Galli; William Gennari; Valeria Ghisetti; Andrea Giacometti; Caterina Gori; Andrea Gori; Roberto Gulminetti; Francesco Leoncini; Gaetano Maffongelli; Franco Maggiolo; Giuseppe Manca; Franco Gargiulo; Canio Martinelli; Renato Maserati; Francesco Mazzotta; Genny Meini; Valeria Micheli; Laura Monno; Cristina Mussini; Pasquale Narciso; Silvia Nozza; Stefania Paolucci; Giorgio Pal; Saverio Parisi; Giustino Parruti; Angela Rosa Pignataro; Michela Pollicita; Tiziana Quirino; Maria Carla Re; Giuliano Rizzardini; Rosaria Santangelo; Renzo Scaggiante; Gaetana Sterrantino; Ombretta Turriziani; Maria Linda Vatteroni; Laura Vecchi; Claudio Viscoli; Vincenzo Vullo; Maurizio Zazzi; Adriano Lazzarini; Carlo Federico Perno
Journal:  New Microbiol       Date:  2012-01-10       Impact factor: 2.479

2.  Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory.

Authors:  Christian Paar; Maria Geit; Herbert Stekel; Jörg Berg
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

3.  Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

Authors:  Rachel A McGovern; Alexander Thielen; Simon Portsmouth; Theresa Mo; Winnie Dong; Conan K Woods; Xiaoyin Zhong; Chanson J Brumme; Douglass Chapman; Marilyn Lewis; Ian James; Jayvant Heera; Hernan Valdez; P Richard Harrigan
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

4.  Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice.

Authors:  J Symons; L Vandekerckhove; R Paredes; C Verhofstede; R Bellido; E Demecheleer; P M van Ham; S F L van Lelyveld; A J Stam; D van Versendaal; M Nijhuis; A M J Wensing
Journal:  Clin Microbiol Infect       Date:  2011-09-09       Impact factor: 8.067

5.  Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.

Authors:  Elise Tu; Luke C Swenson; Sally Land; Sarah Pett; Sean Emery; Kat Marks; Anthony D Kelleher; Steve Kaye; Rolf Kaiser; Eugene Schuelter; Richard Harrigan
Journal:  J Clin Microbiol       Date:  2013-04-17       Impact factor: 5.948

6.  The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing.

Authors:  Valentina Svicher; Valeria Cento; Gabriella Rozera; Isabella Abbate; Maria Mercedes Santoro; Daniele Armenia; Lavinia Fabeni; Alessandro Bruselles; Alessandra Latini; Guido Palamara; Valeria Micheli; Giuliano Rizzardini; Caterina Gori; Federica Forbici; Giuseppe Ippolito; Massimo Andreoni; Andrea Antinori; Francesca Ceccherini-Silberstein; Maria Rosaria Capobianchi; Carlo Federico Perno
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.